Bristol-Myers Squibb Company (BMY) Price CAGR:11.85%(TTM)
The price cagr for Bristol-Myers Squibb Company (BMY) is +11.85% over the latest trailing 12-month period. The comparable SPY value is +20.75%. Year-to-date price return is +4.54%. Price CAGR uses adjusted close price history and excludes dividends.
The price CAGR for Bristol-Myers Squibb Company (BMY) stock is 11.85% over the past 12 months. The 3 year CAGR is -4.81% and the 5 year CAGR is -3.68%. The price CAGR (Compound Annual Growth Rate) shows how Bristol-Myers Squibb Company's stock price has grown over various time periods. This measures pure price appreciation without including dividends.
BMY Price CAGR Chart
Bristol-Myers Squibb Company (BMY)
BMY Price CAGR History
| Year | Start Price | End Price | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | 42.23 | 46.65 | +4.42 | +10.47% | +10.47% |
| 2024 | 65.30 | 42.23 | -23.07 | -35.33% | -35.33% |
| 2023 | 76.47 | 65.30 | -11.17 | -14.61% | -14.61% |
| 2022 | 66.83 | 76.47 | +9.64 | +14.42% | +14.42% |
| 2021 | 56.41 | 66.83 | +10.42 | +18.47% | +18.47% |
| 2020 | 48.89 | 56.41 | +7.52 | +15.38% | +15.38% |
| 2019 | 53.64 | 48.89 | -4.75 | -8.86% | -8.86% |
| 2018 | 55.22 | 53.64 | -1.58 | -2.86% | -2.86% |
| 2017 | 70.67 | 55.22 | -15.45 | -21.86% | -21.86% |
| 2016 | 66.62 | 70.67 | +4.05 | +6.08% | +6.08% |
| 2015 | 48.06 | 66.62 | +18.56 | +38.62% | +38.62% |
| 2014 | 46.85 | 48.06 | +1.21 | +2.58% | +2.58% |
| 2013 | 34.55 | 46.85 | +12.30 | +35.60% | +35.60% |
| 2012 | 27.42 | 34.55 | +7.13 | +26.00% | +26.00% |
| 2011 | 25.88 | 27.42 | +1.54 | +5.95% | +5.95% |
| 2010 | 19.38 | 25.88 | +6.50 | +33.54% | +33.54% |
| 2009 | 20.06 | 19.38 | -0.68 | -3.39% | -3.39% |
| 2008 | 30.76 | 20.06 | -10.70 | -34.79% | -34.79% |
| 2007 | 24.75 | 30.76 | +6.01 | +24.28% | +24.28% |
| 2006 | 25.46 | 24.75 | -0.71 | -2.79% | -2.79% |
| 2005 | 25.84 | 25.46 | -0.38 | -1.47% | -1.47% |
| 2004 | 27.10 | 25.84 | -1.26 | -4.65% | -4.65% |
| 2003 | 26.88 | 27.10 | +0.22 | +0.82% | +0.82% |
| 2002 | 53.97 | 26.88 | -27.09 | -50.19% | -50.19% |
| 2001 | 50.05 | 53.97 | +3.92 | +7.83% | +7.83% |
| 2000 | 64.09 | 50.05 | -14.04 | -21.91% | -21.91% |
| 1999 | 53.41 | 64.09 | +10.68 | +20.00% | +20.00% |
| 1998 | 36.24 | 53.41 | +17.17 | +47.38% | +47.38% |
| 1997 | 21.04 | 36.24 | +15.20 | +72.24% | +72.24% |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner